Latest Atheroma Stories
Scientists and engineers at UC Santa Barbara and other researchers have developed a nanoparticle that can attack plaque â€“â€“ a major cause of cardiovascular disease.
BURLINGTON, Mass. and ROTTERDAM, Netherlands, May 19 /PRNewswire/ -- InfraReDx, Inc. announced today the first use in patients of a novel coronary catheter that uses both light and sound to image coronary plaques. Working on a team led by Dr. Patrick Serruys, Dr.
Comprehensive Phase 2 Program Combines Histology, Biomarkers and Non-Invasive Imaging to Demonstrate Mechanism of Action and Positive Impact on Vascular Inflammation SAN FRANCISCO, May 14 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc.
U.S. researchers say they have evidence to explain what separates average blood vessel plaque from those that trigger blood clots. The study, published in the journal Cell Metabolism, suggest drugs designed to tackle a form of cellular stress might be useful in treating heart disease.
A common misconception about arterial plaque is that it inevitably leads to a heart attack or a stroke.
Data Presented at American Heart Association ATVB Conference Shows Reduction in Non-Calcified Plaque Volume and Fewer New Plaque Lesions in Treated Patients WASHINGTON and SAN FRANCISCO, May 1 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc.
German researchers identified 17 protein biomarkers linked to coronary artery disease, which may result in a urine test to screen for heart disease. Clinicians now diagnose the disease using coronary angiogrography -- an X-ray examination of the blood vessels or heart chambers.
Proteome analysis, a screening requiring only a patient's urine specimen, shows promise as a reliable and noninvasive way to diagnose atherosclerosis and coronary artery disease in the future, according to research presented at the American Heart Association's Arteriosclerosis, Thrombosis and Vascular Biology Annual Conference 2009.
Data from ACS Phase 2 MDCT Sub-study to be Released Concurrent with AHA Presentation SAN FRANCISCO, March 31 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc.
SAN FRANCISCO, Feb. 25 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced the issuance of United States Patent No.
- A poem in which the author retracts something said in an earlier poem.